SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCOctober 1, 2026

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

Uncommon EGFR exon 19 deletion subtypes were associated with shorter progression-free survival on osimertinib than the common E746_A750del deletion, in a multicentre retrospective study published in Lung Cancer, with the L747_A750delinsP subtype standing out as potentially high risk.
Share

In brief

  • In a multicentre retrospective study of 111 patients with advanced EGFR exon 19 deletion-positive NSCLC treated with osimertinib, 86.5% received the drug as first-line therapy.
  • Patients with deletions other than E746_A750del (n=25) had a shorter median progression-free survival (PFS) than those with E746_A750del (n=86): 14.3 vs 20.6 months, p<0.05.
  • The four patients with L747_A750delinsP had a median PFS of 3.5 months and a median overall survival (OS) of 11.8 months, against 20.6 and 48.5 months with E746_A750del (both p<0.001).
  • In public genomic databases, non-E746_A750del deletions carried more RBM10 co-mutations.
  • L747_A750delinsP was characterised by frequent CDKN2A/B homozygous deletions and MYC amplifications.

Study at a glance

  • Design: multicentre retrospective cohort, with genomic analysis of AACR Project GENIE and MSK-CHORD data
  • Population: 111 patients with advanced EGFR exon 19 deletion-positive NSCLC
  • Treatment: osimertinib, first line in 86.5%
  • Groups: E746_A750del (n=86) and other exon 19 deletions (n=25), including L747_A750delinsP (n=4)
  • Median PFS: 20.6 months (E746_A750del) vs 14.3 months (other deletions), p<0.05
  • L747_A750delinsP (n=4): median PFS 3.5 months, median OS 11.8 vs 48.5 months with E746_A750del (both p<0.001)
  • Co-alterations: RBM10 in non-E746_A750del; CDKN2A/B homozygous deletion and MYC amplification in L747_A750delinsP
  • Not reported: hazard ratios, adjustment for other prognostic factors, and OS for the non-E746_A750del group as a whole (in the abstract)

Exon 19 deletions differ, and osimertinib data by subtype are scarce

E746_A750del is the most frequent of the EGFR exon 19 deletions, and the authors set out to test whether the rarer variants behave differently on osimertinib, for which subtype-level evidence has been limited.

Differences in survival between exon 19 deletion subtypes have been suggested after treatment with EGFR tyrosine kinase inhibitors. The authors note that the biological mechanisms behind any such difference are poorly understood, which is why the study pairs its clinical cohort with a genomic analysis.

A 6-month shorter median PFS with the less common deletions

Median PFS was 14.3 months in the 25 patients whose tumours carried a deletion other than E746_A750del, compared with 20.6 months in the 86 patients with E746_A750del (p<0.05).

Most of the cohort (86.5%) received osimertinib as first-line therapy, so the comparison largely reflects the setting in which the drug is now standard. The design is retrospective, the smaller group has 25 patients, and the abstract gives the result as p<0.05 without an exact value.

L747_A750delinsP: a median PFS of 3.5 months in four patients

Compared with E746_A750del, the delinsP subtype had a median PFS of 3.5 versus 20.6 months and a median OS of 11.8 versus 48.5 months, both with p<0.001.

The size of the gap is large, and it rests on four patients. The authors describe L747_A750delinsP as potentially a high-risk subtype, and that qualification matches the evidence: a finding of this size in so small a group needs confirmation in a larger series before it could inform treatment decisions.

RBM10 co-mutations in the uncommon deletions, CDKN2A/B loss and MYC gain in delinsP

These co-alterations come from whole-exome sequencing data in the AACR Project GENIE registry and the MSK-CHORD real-world dataset, not from the treated cohort itself.

Non-E746_A750del deletions showed a higher rate of RBM10 co-mutations. L747_A750delinsP was characterised by frequent CDKN2A/B homozygous deletions and MYC amplifications. The authors conclude that differences in co-occurring genomic alterations may contribute to the prognostic heterogeneity among exon 19 deletion subtypes. Because the genomic findings come from public databases rather than the treated cohort, that link remains a hypothesis.

Sources

  1. Lung Cancer. Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer (2026-08-31). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Hidehito Horinouchi.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
Girard ADCs
Oct 05 2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Sandip Patel & Giannis Mountzios
Oct 04 2024
ILCS 2024
Advanced NSCLC

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

} 33 min

G. MountziosS. Patel
Biagio Ricciuti
Oct 04 2024
ILCS 2024
Targeted Therapies

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

} 25 min

B. Ricciuti
Roberto Ferrara
Oct 04 2024
ILCS 2024
Targeted Therapies

Rare But Actionable: How To Target for RET, METex14 and NTRK

} 20 min

R. Ferrara
Anne-Marie Dingemans
Oct 04 2024
ILCS 2024
Targeted Therapies

Current Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

} 25 min

A. Dingemans
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Oct252026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

M. ReckS. PetersG. MountziosN. Reguart
Articles
Oct 01 2026
RESEARCH
Targeted Therapies

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

B. RicciutiJ. RemonD. Planchard
Sep 30 2026
RESEARCH
Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

C. Rolfo
Sep 26 2026
RESEARCH
Advanced NSCLCImmunotherapies

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

B. Ricciuti
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Portrait of Dr. Alexander Drilon
Sep 23 2026
CONGRESS
Advanced NSCLCTargeted Therapies

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 18 2026
INDUSTRY NEWS
Advanced NSCLCTargeted Therapies

Sevabertinib approved in the US for untreated HER2-mutant NSCLC

Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 17 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

D. Planchard
Sep 16 2026
CONGRESS
Advanced NSCLCADCs

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 16 2026
CONGRESS
SCLCTargeted Therapies

Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan

Sep 15 2026
CONGRESS
Advanced NSCLCImmunotherapies

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Advanced NSCLCTargeted Therapies

REZILIENT 3: zipalertinib plus chemotherapy adds six months of first-line PFS

Sep 14 2026
CONGRESS
Resectable NSCLCTargeted Therapies

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

Sep 14 2026
CONGRESS
Advanced NSCLCTargeted Therapies

ARROS-1: first-line zidesamtinib responds in over 90% of ROS1-positive NSCLC

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 14 2026
CONGRESS
Advanced NSCLCADCs

DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain

Sep 14 2026
CONGRESS
Advanced NSCLCTargeted Therapies

PAPILLON final OS: 34.3 vs 27.9 months, HR 0.87 not significant after 76% crossover

Sep 13 2026
CONGRESS
Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months

Giannis Mountzios
Sep 13 2026
CONGRESS
Advanced NSCLCADCsImmunotherapies

EVOKE-03: sacituzumab govitecan plus pembrolizumab misses both primary endpoints

G. Mountzios